DSSConsumer Cyclical · Packaging & Containers

DSS Stock Forecast: DSS, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$0.70

−2.62% on the day

The 1 Wall Street analysts covering DSS, Inc. hold a median 12-month price target of $3 — +327.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 17 Sept 2026 — in the upper half.

Market cap

$7.5M

Ticker Nerd rank

63 / 100

Median analyst target

$3.00

Analysts covering

Revenue$3.6M−31.8% y/y

Operating income−$3.8M

Net income−$5.0M

Free cash flow−$1.9M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−3.0%

+25.2%

YTD

−24.5%

−46.1%

From 52W high

−52.5%

From 52W low

+66.9%

$0.42

$1.48

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

DSS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DSS, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026

63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Accruals

Volatility

Issuance

Momentum

Value

Revisions

Quality

Size (94): Smaller than most of the companies we track.

Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DSS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DSS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $3.00Median $3.00High $3.00

The green dot is the last close — the median target sits +327.9% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
24 June 2020	Aegis Capital	Assumes	Buy	$14
22 July 2013	Dawson James	Initiates	Buy	$4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DSS appears on the weeks it earns a place.

Performance

DSS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, DSS, Inc. returned −46.1% against +16.3% for the S&P 500, dividends included.

DSS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DSS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

DSS, Inc. (DSS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.3×
Price / sales: 0.4×
Price / book: 0.9×
EV / EBITDA: −4.0×

Growth & margins

Revenue growth (YoY): −31.8%
Earnings growth (YoY): −31.8%
Gross margin: −25.4%
Operating margin: −105.0%
Net margin: −148.4%

Returns & dividend

Return on equity: −172.2%
Return on assets: −12.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DSS, Inc. (DSS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

DSS, Inc. has a market value of $7.5M and an enterprise value of $54.3M.
Revenue in the twelve months to 30 June 2026: $18.5M. The latest quarter shrank 31.8% year on year.
Net income over the same four quarters: −$31.0M, a −168.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$11.0M.
Shares outstanding: 10.0M.
Trailing P/E: −0.3×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.
DSS, Inc. employs 102 people — $181K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Sept 2026

Data provided by Twelve Data

Peers

DSS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPackaging & Containers

Company	Market cap	TKN rank
DSSDSS, Inc.	$7.5M	63
YHGJYunhong Green CTI Ltd.	$6.9M	49
MGIHMillennium Group International Holdings Ltd.	$17.6M	33
LOBOLOBO Technologies Ltd.*	$7.5M	20
BGIBirks Group, Inc.*	$6.9M	—
REBNReborn Coffee, Inc.*	$6.9M	18
INEOINNEOVA Holdings Ltd.*	$6.7M	33

* Nearest Consumer Cyclical names by size — few packaging & containers companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DSS, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DSS news & analysis

DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical's Proposed Business Combination with Zoar Limited

GlobeNewsWire · 16 Sept 2026neutral

DSS, Inc. announced that Zoar Limited has filed a Registration Statement on Form F-4 with the SEC in connection with the previously announced proposed business combination involving Impact Biomedical Inc., Zoar, and certain related parties.

Why it matters — The filing marks a procedural step in advancing the previously announced business combination involving Impact Biomedical, which DSS watchers would track.

DSS, Inc. Launches DSS Robotics to Bring AI-Powered Automation to Enterprise Operations

GlobeNewsWire · 8 Sept 2026positive

DSS, Inc. announced the launch of DSS Robotics, a new business focused on practical robotics and intelligent automation solutions for enterprise operations. The company plans to establish a Rochester innovation center for live deployments and customer demonstrations.

Why it matters — The new DSS Robotics unit marks DSS's expansion into AI-powered automation and a new revenue growth avenue, which DSS watchers would see as a notable strategic development.

DSS, Inc. Announces Decision Not to Proceed with Proposed Public Offering

GlobeNewsWire · 4 Sept 2026neutral

DSS, Inc. announced it will not proceed with its previously proposed public offering of Common Stock. The decision was made after further consideration due to limited capacity available under its existing shelf registration statement.

Why it matters — A DSS watcher would care because the company's decision to cancel its planned equity offering could affect its capital-raising plans and financial flexibility.

DSS, Inc. Announces Launch of Proposed Public Offering

GlobeNewsWire · 4 Sept 2026neutral

DSS, Inc. announced that it has commenced a public offering to offer and sell shares of its Common Stock. The company operates across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management.

Why it matters — A DSS watcher would care because the launch of a proposed public offering could affect the company's share count and capital structure.

FAQ

Frequently asked questions about DSS stock

What is the DSS stock price forecast for 2026-2027?

The 1 Wall Street analysts covering DSS, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DSS stock a buy right now?

Of the 1 analysts covering DSS, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DSS, Inc. 63 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DSS?

As at 17 Sept 2026, DSS, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will DSS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +327.9% from the last close, and Ticker Nerd's factor model ranks DSS, Inc. 63 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DSS stock forecast for 2030?

No analyst covering DSS, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DSS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.

How has DSS stock performed over the past year?

DSS, Inc. returned -46.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DSS, Inc. do?

DSS Inc. is a diversified company that operates across product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing.

What is the latest news on DSS?

The most recent item we track (GlobeNewsWire, 16 Sept 2026): "DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical's Proposed Business Combination with Zoar Limited". DSS, Inc. announced that Zoar Limited has filed a Registration Statement on Form F-4 with the SEC in connection with the previously announced proposed business combination involving Impact Biomedical Inc., Zoar, and certain related parties.

Company

About DSS, Inc.

DSS Inc. is a diversified company that operates across product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing. DSS Inc. develops and sells custom folding cartons, mailers, photo sleeves, and other specialized packaging and document security products used to protect information and support branded product presentation. In healthcare and biohealth, the company focuses on health information technology, software development, systems integration, and solutions that support patient safety, regulatory compliance, and digital transformation. Its financial services activities include commercial lending and investment-related services, while its direct marketing business distributes products and services through partner networks and digital channels. DSS Inc. serves a mix of commercial, institutional, and public-sector customers, with a notable presence in healthcare and enterprise services.

CEO Mr. Jason T. Grady · 102 employees · United States · https://www.dssworld.com